Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)

BACKGROUND: The treatment of levodopa‐induced dyskinesia in Parkinson's disease (PD) is an unmet need with no approved drug therapy. OBJECTIVE: The purpose of this study was to investigate the efficacy and safety of 274 mg ADS‐5102 (amantadine) extended‐release capsules (equivalent to 340‐mg am...

Descripción completa

Detalles Bibliográficos
Autores principales: Oertel, Wolfgang, Eggert, Karla, Pahwa, Rajesh, Tanner, Caroline M., Hauser, Robert A., Trenkwalder, Claudia, Ehret, Reinhard, Azulay, Jean Philippe, Isaacson, Stuart, Felt, Larissa, Stempien, Mary Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763269/
https://www.ncbi.nlm.nih.gov/pubmed/28833562
http://dx.doi.org/10.1002/mds.27131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763269/
https://www.ncbi.nlm.nih.gov/pubmed/28833562
http://dx.doi.org/10.1002/mds.27131

Ejemplares similares